Hello Alpha’s Post

Great deep dive by Anastassia Gliadkovskaya on obesity treatment disparities. GLP-1s have the potential to profoundly tackle inequity in obesity care. Sadly, they will do the opposite if we do not radically innovate the way we deliver care. Obesity is complex and hard to treat. Complex social+ economic conditions alongside chronic exposure to obesogens can't be tackled with a prescribe-and-forget, service model. 🤝 If you're a clinic or health system and passionate about comprehensive, personalized, and community driven care, join Enara Health's obesity care network. Together, we can shift the paradigm in healthcare delivery. #obesity #inequity #healthcaredisparities #zepbound #wegovy #ozempic FierceHealthcare

A new framework for the diagnosis, staging and management of obesity in adults https://lnkd.in/etRMgDEH #MedicalAdvances #Science

On #WorldObesityDay let's stop the #stigma and recognize (& address) its #bidirectional nature with other #diseases & #publichealth #risks. What is stigma? We can think about it as someone’s perception of actual or potential negative treatment stemming from an individual characteristic. #Stigmatization on account of #bodyweight has been long observed - and needs to stop. Stigma is closely associated with, yet distinct from, #discrimination. Concern about feelings of stigma or perceived risks of discrimination may be enough to hinder personal choices (such as seeking #health and #wellness services). In other words, people can feel stigma with & without actual discrimination. What is "bidirectional"? This means that one disease or condition can cause &/or be caused by another disease or condition. It is increasingly clear that obesity is bidirectional with a wide range of other conditions, diseases and health risks. This includes, but is by no means limited to, the area I presently focus on: #MASLD (#metabolicdysfunctionassociatedsteatoticliverdisease). As a matter of #government #policy, #healthsystems practice and, frankly, inter-personal neighborliness, we can, should and must do more to reduce and eliminate obesity-associated stigma. See for example Zobair Younossi & co-authors here about stigma & discrimination in relation to MASLD: https://lnkd.in/dfSsysjV Further, we can, should and must do more to address the bidirectional nature of obesity in relation to a wide-range of diseases and public health risks. See for example Paul Brennan Prof. Shira Zelber Sagi Alina M. Allen Jeffrey V. Lazarus & Prof. John Dillon here: https://lnkd.in/dsyscTX5 cc: EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER American Association for the Study of Liver Diseases (AASLD) Global NASH Council Fatty Liver Alliance #metabolicsyndrome #liverhealth #healthmatters #endstigma

While those slow to the party are still asking the question “Is obesity a disease?”…. …. Leaders in this field, such as Prof Carel le Roux and Dr Werd Al-Najim (founding clinicians of Beyondbmi ) who are part of IMI_SOPHIA , a collaborative research initiative led by the European Union, are asking the more nuanced question of… 🤔Is obesity, in fact, multiple diseases? Prof le Roux states obesity can no longer be seen as a single homogeneous pathology but rather should be viewed as clinical conditions affecting various subpopulations that respond differently to treatments. "When we talk about 'obesities' and not 'obesity,' we can also conduct our consultations more carefully by explaining to our patients that if they do not respond to treatment, it is not their fault, not because they did something wrong, but because of something that is not usually taken into account, such as the presence of comorbidities, or even personal characteristics and lifestyle, such as age and smoking," said Le Roux. Read more here: The SOPHIA Project Conceives of Obesity Beyond BMI https://lnkd.in/eeARpy9e #obesity #obesitymedicine #digitalhealth #weightloss #healthgain #bariatricmedicine

Dr. Mikhail Kosiborod and colleagues followed up their publication last week on the effect of #semaglutide in #heart failure patients, with a further study reported in Nature Medicine this week. The finding of key importance ‘…in patients treated with semaglutide, increased degree of weight loss was associated with increased magnitude of improvements in #symptoms, #physical limitations and #inflammation...’ such that ‘…the effects of semaglutide-induced weight loss are not restricted to individuals with very high #BMI but apply across the entire spectrum of obesity.’ My take away is that weight loss is an effective treatment strategy for patients with heart failure, and can benefit patients even with a milder degree of obesity, such as those with class 1 obesity, defined by a body mass index of between 30-35. https://lnkd.in/eq7TEpW9

🔍 Are you interested in #obesity therapy and the latest trends in #patientcare within the obesity space? We are thrilled to share the most recent IMI_SOPHIA publication on the need for a new approach to obesity treatment. 🌍 Obesity currently affects the lives of 650 million people worldwide. As this number is growing, the need for better treatment options is rising. The unmet medical need among patients requires a fundamental change in the approach to obesity therapy. 🔬 By viewing obesity as a set of different diseases and changing its narrative, we can improve treatment outcomes for patients. Revolutionizing research and clinical perspectives around obesity requires partnerships involving all stakeholders and a new vocabulary and terminology 💪 Let's work together to break down existing barriers and create shared value! 👏Thank you to the authors of the for this critical contribution to the study of obesity treatment! Abd Tahrani, Marina Panova-Noeva, MD, MSc, PhD, Nanette Schloot, Anita M. Hennige, MD, Jeannette Söderberg, Joe Nadglowski, Lisa Tarasenko, Nadia Ahmad, Barbara Sleypen, Rafael Bravo, Werd Al-Najim, Carel le Roux University College Dublin, JDRF International, Obesity Action Coalition, Medtronic EFPIA - European Federation of Pharmaceutical Industries and Associations, Innovative Health Initiative (IHI) #HealthcareInnovation #IMISOPHIA #PersonalizedTreatment #ObesityScience https://lnkd.in/ePHKXwqS

Can a vibrating device stop you from being hungry? Read our latest article to learn how scientists at @Massachusetts Institute of Technology have developed a vibrating ingestible pill to combat obesity! #medicalnews #medicaldevice #technology #obesity #medicalnewsbulletin

Impressed how Novo is handeling worldwide obesity space, from all angles. Providers, patients, payors, policy, competition, supply shortages, press, reputation……just all. #fightobesity #innovationinhealthcare #researchanddevelopment

#Obesity and #hypertension? Effective obesity #treatment can put the hypertension into remission. Two new studies offer compelling data. https://lnkd.in/eqZFQPVA

It’s interesting to note that this paper considers abdominal fat accumulation an important novelty in their framework regarding the anthropometric component of obesity diagnosis (https://lnkd.in/gcg9Kxgv). The basis for this change is the recognition that BMI alone is insufficient as a diagnostic criterion, and that body fat distribution significantly affects health. At Medika Natura Sdn Bhd, we have already recognized in our clinical studies that BMI alone is inadequate as a diagnostic criterion, and that body fat distribution has a significant impact on health. You can read our clinical publication here https://lnkd.in/gg_iQTr4 #abdominalobesity